Mitigation of human-pathogenic fungi that exhibit resistance to medical agents: can clinical antifungal stewardship help?
Reducing indiscriminate antimicrobial usage to combat the expansion of multidrug-resistant human-pathogenic bacteria is fundamental to clinical antibiotic stewardship. In contrast to bacteria, fungal resistance traits are not understood to be propagated via mobile genetic elements, and it has been proposed that a global explosion of resistance to medical antifungals is therefore unlikely. Clinical antifungal stewardship has focused instead on reducing the drug toxicity and high costs associated with medical agents. Mitigating the problem of human-pathogenic fungi that exhibit resistance to antimicrobials is an emergent issue. This article addresses the extent to which clinical antifungal stewardship could influence the scale and epidemiology of resistance to medical antifungals both now and in the future. The importance of uncharted selection pressure exerted by agents outside the clinical setting (agricultural pesticides, industrial xenobiotics, biocides, pharmaceutical waste and others) on environmentally ubiquitous spore-forming molds that are lesserstudied but increasingly responsible for drug-refractory infections is considered.
Swansea University, College of Medicine, Institute of Life Science: Microbes & Immunity, SA2 8PP, Wales, UK.
Claire M
CM
Hull
Nicola J
NJ
Purdy
Suzy C
SC
Moody
D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D025141:Drug Resistance, Fungal; D004783:Environmental Microbiology; D005658:Fungi / Q000187:drug effects* / Q000502:physiology; D054884:Host-Pathogen Interactions; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D012307:Risk Factors
D000935:Antifungal Agents